CN110494452B - 结合steap-1的抗体 - Google Patents

结合steap-1的抗体 Download PDF

Info

Publication number
CN110494452B
CN110494452B CN201880020414.7A CN201880020414A CN110494452B CN 110494452 B CN110494452 B CN 110494452B CN 201880020414 A CN201880020414 A CN 201880020414A CN 110494452 B CN110494452 B CN 110494452B
Authority
CN
China
Prior art keywords
antigen binding
fab
seq
domain
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880020414.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN110494452A (zh
Inventor
T·霍夫
M·科尼格
E·莫斯纳
J·尼沃纳
T·韦因策尔
L·拉里维尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of CN110494452A publication Critical patent/CN110494452A/zh
Application granted granted Critical
Publication of CN110494452B publication Critical patent/CN110494452B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Reproductive Health (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN201880020414.7A 2017-04-03 2018-03-29 结合steap-1的抗体 Active CN110494452B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17164466.9 2017-04-03
EP17164466 2017-04-03
PCT/EP2018/058043 WO2018184966A1 (en) 2017-04-03 2018-03-29 Antibodies binding to steap-1

Publications (2)

Publication Number Publication Date
CN110494452A CN110494452A (zh) 2019-11-22
CN110494452B true CN110494452B (zh) 2023-08-25

Family

ID=58489188

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880020414.7A Active CN110494452B (zh) 2017-04-03 2018-03-29 结合steap-1的抗体

Country Status (20)

Country Link
US (3) US11180571B2 (enExample)
EP (1) EP3606963B1 (enExample)
JP (1) JP7247101B2 (enExample)
KR (1) KR102667951B1 (enExample)
CN (1) CN110494452B (enExample)
AU (1) AU2018247767B2 (enExample)
BR (1) BR112019018767A2 (enExample)
CA (1) CA3055132A1 (enExample)
CL (1) CL2019002735A1 (enExample)
CO (1) CO2019010164A2 (enExample)
CR (1) CR20190430A (enExample)
ES (1) ES2955852T3 (enExample)
IL (1) IL269394A (enExample)
MA (1) MA49289A (enExample)
MX (1) MX2019011769A (enExample)
PE (1) PE20200010A1 (enExample)
PH (1) PH12019502274A1 (enExample)
RU (1) RU2019134462A (enExample)
SG (1) SG11201909218RA (enExample)
WO (1) WO2018184966A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020026724A2 (pt) 2018-07-02 2021-03-30 Amgen Inc. Proteína de ligação ao antígeno anti-steap1
JP2022512798A (ja) * 2018-10-25 2022-02-07 エフ．ホフマン－ラ ロシュ アーゲー 抗体ＦｃＲｎ結合の改変
CA3132275A1 (en) * 2019-04-25 2020-10-29 Ulrich Brinkmann Generation of antibody-derived polypeptides by polypeptide chain exchange
AU2020343652A1 (en) * 2019-09-05 2022-03-24 Memorial Sloan Kettering Cancer Center Anti-STEAP1 antibodies and uses thereof
WO2023164510A1 (en) 2022-02-23 2023-08-31 Xencor, Inc. Anti-cd28 x anti-psma antibodies
MX2024010773A (es) * 2022-03-03 2024-09-10 Pfizer Anticuerpos multiespecificos y usos de estos.
GB202208119D0 (en) 2022-06-01 2022-07-13 Univ Oslo Hf Anti-steap1 car
WO2024192308A2 (en) * 2023-03-14 2024-09-19 Xencor, Inc. Anti-cd28 compositions
AU2023448948A1 (en) * 2023-05-24 2025-10-09 Hangzhou Dac Biotech Co., Ltd Targeted treatment of prostate cancers and other tumors by an antibody-drug conjugate

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113601A2 (en) * 2004-04-22 2005-12-01 Agensys, Inc. Antibodies and molecules derived therefrom that bind to steap-1 proteins
WO2008052187A2 (en) * 2006-10-27 2008-05-02 Genentech. Inc. Antibodies and immunoconjugates and uses therefor
WO2015149077A1 (en) * 2014-03-28 2015-10-01 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
CN106413756A (zh) * 2014-01-24 2017-02-15 豪夫迈·罗氏有限公司 使用抗steap1抗体和免疫缀合物的方法

Family Cites Families (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US830930A (en) 1905-11-22 1906-09-11 E & T Fairbanks & Co Weighing-scale.
CH605550A5 (enExample) 1972-06-08 1978-09-29 Research Corp
CA1096187A (en) 1977-04-18 1981-02-24 Souhei Monden Ornament adapted to be fixed by permanent magnets
US4526988A (en) 1983-03-10 1985-07-02 Eli Lilly And Company Difluoro antivirals and intermediate therefor
DE3316828C1 (de) 1983-05-07 1984-07-12 Fritz 4902 Bad Salzuflen Steffen Arbeitsmappe
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5597531A (en) 1985-10-04 1997-01-28 Immunivest Corporation Resuspendable coated magnetic particles and stable magnetic particle suspensions
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1990005144A1 (en) * 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
US5698271A (en) 1989-08-22 1997-12-16 Immunivest Corporation Methods for the manufacture of magnetically responsive particles
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
DE122004000008I1 (de) 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
JPH08500962A (ja) 1992-02-06 1996-02-06 クリエイティブ バイオモレキュルズ，インコーポレイテッド 癌マーカー用生物合成結合蛋白質
US5489525A (en) 1992-10-08 1996-02-06 The United States Of America As Represented By The Department Of Health And Human Services Monoclonal antibodies to prostate cells
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
CA2153480A1 (en) 1993-11-12 1995-06-01 Kenichi Matsubara Gene signature
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US5859045A (en) 1996-05-08 1999-01-12 Novo Nordisk A/S Novo Alle Crystalline -! 3R 4R-trans-7 methoxy 2,2-dimethyl1-3-phenyl 1-4 4-12 pyrrolidin-1 -Y1!ethoxyl 1!chromane hydrogen fumarate
US5824504A (en) 1996-09-26 1998-10-20 Elshourbagy; Nabil A. Human 7-transmembrane receptor and DNA
AU5243198A (en) 1996-10-30 1998-05-22 Uab Research Foundation, The Enhancement of tumor cell chemosensitivity and radiosensitivity using single chain intracellular antibodies
BR9808881A (pt) 1997-02-25 2001-09-11 Corixa Corp Compostos para imunoterapia de câncer de próstata e métodos para seu uso
CA2281954A1 (en) 1997-02-25 1998-08-27 Corixa Corporation Compounds for immunodiagnosis of prostate cancer and methods for their use
US6800746B2 (en) 1997-02-25 2004-10-05 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
AU751659B2 (en) 1997-05-02 2002-08-22 Genentech Inc. A method for making multispecific antibodies having heteromultimeric and common components
WO1998053071A1 (en) 1997-05-23 1998-11-26 Biogen, Inc. Modulators of tissue regeneration
ES2244066T3 (es) 1997-06-24 2005-12-01 Genentech, Inc. Procedimiento y composiciones de glicoproteinas galactosiladas.
ES2267192T3 (es) 1997-08-01 2007-03-01 Serono Genetics Institute S.A. Ests 5' para proteinas secretadas no especificas de tejido.
WO1999006550A2 (en) 1997-08-01 1999-02-11 Genset 5' ESTs FOR SECRETED PROTEINS EXPRESSED IN PROSTATE
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
JPH1164691A (ja) 1997-08-25 1999-03-05 Furukawa Electric Co Ltd:The 無切断クリップ
US20030060612A1 (en) 1997-10-28 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
ATE419009T1 (de) 1997-10-31 2009-01-15 Genentech Inc Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
ES2375931T3 (es) 1997-12-05 2012-03-07 The Scripps Research Institute Humanización de anticuerpo murino.
WO1999041613A1 (en) 1998-02-12 1999-08-19 Immunivest Methods and reagents for the rapid and efficient isolation of circulating cancer cells
PT2180007E (pt) 1998-04-20 2013-11-25 Roche Glycart Ag Engenharia de glicosilação de anticorpos para melhorar a citotoxicidade celular dependente de anticorpos
US20030064397A1 (en) 1998-05-22 2003-04-03 Incyte Genomics, Inc. Transmembrane protein differentially expressed in prostate and lung tumors
US6048970A (en) 1998-05-22 2000-04-11 Incyte Pharmaceuticals, Inc. Prostate growth-associated membrane proteins
US6833438B1 (en) 1999-06-01 2004-12-21 Agensys, Inc. Serpentine transmembrane antigens expressed in human cancers and uses thereof
US20030149531A1 (en) 2000-12-06 2003-08-07 Hubert Rene S. Serpentine transmembrane antigens expressed in human cancers and uses thereof
PT1086223E (pt) 1998-06-01 2009-11-03 Agensys Inc Novos antigénios transmembranares em serpentina expressos em cancros humanos e suas utilizações
KR20010083111A (ko) 1998-07-14 2001-08-31 길리스 스티브 전립선암의 치료 및 진단을 위한 조성물 및 방법
JP2002532083A (ja) 1998-12-17 2002-10-02 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４７個のヒト分泌タンパク質
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CA2372053C (en) 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
JP2003502061A (ja) 1999-06-11 2003-01-21 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド ４８個のヒト分泌タンパク質
AU6906800A (en) 1999-08-17 2001-03-13 Incyte Genomics, Inc. Membrane associated proteins
WO2001025272A2 (en) 1999-10-04 2001-04-12 Corixa Corporation Compositions and methods for therapy and diagnosis of prostate cancer
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
ES2248127T3 (es) 1999-10-04 2006-03-16 Medicago Inc. Metodo para regular la transcripcion de genes foraneos en presencia de nigtrogeno.
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
JP2004537252A (ja) 1999-11-12 2004-12-16 コリクサ コーポレイション 前立腺癌の治療及び診断のための組成物及び方法
CA2395053C (en) 1999-12-06 2012-05-29 Agensys, Inc. Novel serpentine transmembrane antigens expressed in human cancers and uses thereof
US20030180714A1 (en) 1999-12-15 2003-09-25 Genentech, Inc. Shotgun scanning
CA2397741A1 (en) 2000-01-14 2001-07-19 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
EP1572987A4 (en) 2000-02-03 2005-11-30 Nuvelo Inc NUCLEIC ACIDS AND POLYPEPTIDES
AU3087801A (en) 2000-02-04 2001-08-14 Molecular Dynamics Inc Human genome-derived single exon nucleic acid probes useful for analysis of geneexpression in human breast and hbl 100 cells
AU2001241541A1 (en) 2000-02-17 2001-08-27 Millennium Predictive Medicine, Inc. Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of human prostate cancer
AU4941101A (en) 2000-03-24 2001-10-08 Fahri Saatcioglu Novel prostate-specific or testis-specific nucleic acid molecules, polypeptides,and diagnostic and therapeutic methods
CA2403909A1 (en) 2000-03-27 2001-10-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of prostate cancer
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
SI2857516T1 (sl) 2000-04-11 2017-09-29 Genentech, Inc. Multivalentna protitelesa in njihove uporabe
WO2001094629A2 (en) 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
US20020177552A1 (en) 2000-06-09 2002-11-28 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
EP1305450A2 (en) 2000-07-28 2003-05-02 Compugen Inc. Oligonucleotide library for detecting rna transcripts and splice variants that populate a transcriptome
KR20030029847A (ko) 2000-08-24 2003-04-16 제넨테크, 인크. 종양의 진단 및 치료를 위한 조성물 및 방법
JP2005506033A (ja) 2000-10-13 2005-03-03 イーオーエス バイオテクノロジー インコーポレイテッド 前立腺癌の診断法、前立腺癌モジュレータースクリーニングの組成物及び方法
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
WO2002059260A2 (en) 2000-11-17 2002-08-01 Hyseq, Inc. Nucleic acids and polypeptides
ES2405944T3 (es) 2000-11-30 2013-06-04 Medarex, Inc. Ácidos nucleicos que codifican las secuencias de inmunoglobulina humana reorganizadas a partir de ratones transcromoscómicos transgénicos zadas
AU2002235871A1 (en) 2001-01-12 2002-07-30 Hybrigenics Protein-protein interactions between shigella flexneri polypeptides and mammalian polypeptides
AU2002320013A1 (en) 2001-03-21 2002-11-18 Human Genome Sciences, Inc. Human secreted proteins
US20030108963A1 (en) 2001-07-25 2003-06-12 Millennium Pharmaceuticals, Inc. Novel genes, compositions, kit, and methods for identification, assessment, prevention and therapy of prostate cancer
NZ603111A (en) 2001-08-03 2014-05-30 Roche Glycart Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
EP2287186B1 (en) 2001-09-06 2014-12-31 Agensys, Inc. Nucleic acid and corresponding protein entitled STEAP-1 useful in treatment and detection of cancer
US7494646B2 (en) * 2001-09-06 2009-02-24 Agensys, Inc. Antibodies and molecules derived therefrom that bind to STEAP-1 proteins
WO2003022955A1 (en) 2001-09-11 2003-03-20 Nessdisplay Co., Ltd. Organic electroluminescent device having a polyimide hole transport layer
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
ES2326964T3 (es) 2001-10-25 2009-10-22 Genentech, Inc. Composiciones de glicoproteina.
EP1308459A3 (en) 2001-11-05 2003-07-09 Research Association for Biotechnology Full-length cDNA sequences
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US20050031613A1 (en) 2002-04-09 2005-02-10 Kazuyasu Nakamura Therapeutic agent for patients having human FcgammaRIIIa
AU2003236020B2 (en) 2002-04-09 2009-03-19 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in GDP-fucose transport
BR0309145A (pt) 2002-04-09 2005-02-01 Kyowa Hakko Kogyo Kk Células das quais o genoma é modificado
JPWO2003085119A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物のＦｃγ受容体ＩＩＩａに対する結合活性を高める方法
JPWO2003085118A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
PT2357006E (pt) 2002-07-31 2016-01-22 Seattle Genetics Inc Conjugados de fármacos e sua utilização para tratamento do cancro, de uma doença autoimune ou de uma doença infeciosa
DE60332957D1 (de) 2002-12-16 2010-07-22 Genentech Inc Immunoglobulinvarianten und deren verwendungen
WO2004065416A2 (en) 2003-01-16 2004-08-05 Genentech, Inc. Synthetic antibody phage libraries
JP5425365B2 (ja) 2003-01-22 2014-02-26 グリカート バイオテクノロジー アクチェンゲゼルシャフト 増加したＦｃレセプター結合親和性およびエフェクター機能を有する抗体を作製するための融合構築物およびその使用
DE602004030220D1 (de) 2003-02-27 2011-01-05 Veridex Llc ZIRKULIERENDE TUMORZELLEN (CTC's): FRÜHE BEURTEILUNG VON TIME-TO-PROGRESSION, ÜBERLEBEN UND ANSPRECHEN AUF THERAPIE BEI PATIENTEN MIT METASTASIERTEM KREBS
WO2004106381A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
SG149815A1 (en) 2003-11-06 2009-02-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
KR101245983B1 (ko) 2004-03-31 2013-06-28 제넨테크, 인크. 인간화 항-ｔｇｆ-베타 항체
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
PL1737891T3 (pl) 2004-04-13 2013-08-30 Hoffmann La Roche Przeciwciała przeciw selektynie p
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
NZ556286A (en) 2005-02-07 2010-11-26 Glycart Biotechnology Ag Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
DK3050963T3 (da) 2005-03-31 2019-12-09 Chugai Pharmaceutical Co Ltd Fremgangsmåde til fremstilling af polypeptid ved regulering af arrangement
CN1870459A (zh) 2005-05-24 2006-11-29 松下电器产业株式会社 联合脏纸编码与调度的多用户多输入多输出跨层通信方法
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
WO2007042261A2 (en) 2005-10-11 2007-04-19 Micromet Ag Compositions comprising cross-species-specific antibodies and uses thereof
US8679490B2 (en) 2005-11-07 2014-03-25 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
EP1999154B1 (en) 2006-03-24 2012-10-24 Merck Patent GmbH Engineered heterodimeric protein domains
WO2007134050A2 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
EP2035456A1 (en) 2006-06-22 2009-03-18 Novo Nordisk A/S Production of bispecific antibodies
US20080044455A1 (en) 2006-08-21 2008-02-21 Chaim Welczer Tonsillitus Treatment
ES2399075T3 (es) 2006-08-30 2013-03-25 Genentech, Inc. Anticuerpos multiespecíficos
UA94628C2 (ru) 2006-10-27 2011-05-25 Дженентек, Инк. Гуманизированное моноклональное антитело, которое связывается с steap-1, и его применение
CN103694350B (zh) 2007-04-03 2018-04-24 安进研发（慕尼黑）股份有限公司 跨物种特异性CD3-ε结合结构域
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US8242247B2 (en) 2007-12-21 2012-08-14 Hoffmann-La Roche Inc. Bivalent, bispecific antibodies
EP2225254A4 (en) 2007-12-27 2011-03-30 Infinity Pharmaceuticals Inc THERAPEUTIC CARE TREATMENTS
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
CN102015998A (zh) 2008-02-01 2011-04-13 加利福尼亚大学董事会 微流体成像细胞分析
IT1391619B1 (it) 2008-11-04 2012-01-11 Silicon Biosystems Spa Metodo per l'individuazione, selezione e analisi di cellule tumorali
KR101676887B1 (ko) 2008-11-20 2016-11-16 제넨테크, 인크. 치료 단백질 제형
CA2756244A1 (en) 2009-04-02 2010-10-07 Roche Glycart Ag Multispecific antibodies comprising full length antibodies and single chain fab fragments
ES2537100T3 (es) 2009-04-07 2015-06-02 Roche Glycart Ag Anticuerpos biespecíficos trivalentes
EP2424567B1 (en) 2009-04-27 2018-11-21 OncoMed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
PE20120540A1 (es) 2009-05-27 2012-05-09 Hoffmann La Roche Anticuerpos triespecificos o tetraespecificos
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
JP5795311B2 (ja) 2009-07-15 2015-10-14 ネステク ソシエテ アノニム 抗体ベースのアレイを使用する胃癌療法のための薬物選択
AU2010296018B2 (en) 2009-09-16 2016-05-05 Genentech, Inc. Coiled coil and/or tether containing protein complexes and uses thereof
US9034658B2 (en) 2009-11-23 2015-05-19 The General Hospital Corporation Microfluidic devices for the capture of biological sample components
NZ600820A (en) 2009-12-29 2014-12-24 Emergent Product Dev Seattle Heterodimer binding proteins and uses thereof
WO2011115892A1 (en) 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
WO2011127219A1 (en) 2010-04-06 2011-10-13 Caris Life Sciences Luxembourg Holdings Circulating biomarkers for disease
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
NZ602840A (en) 2010-06-03 2014-11-28 Genentech Inc Immuno-pet imaging of antibodies and immunoconjugates and uses therefor
AU2011265054B2 (en) 2010-06-08 2016-09-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
CN101943703A (zh) 2010-06-28 2011-01-12 首都医科大学 一种基于纳米技术的微量蛋白质检测方法
RS59589B1 (sr) 2010-11-05 2019-12-31 Zymeworks Inc Dizajniranje stabilnog heterodimernog antitela sa mutacijama u fc domenu
KR20160044598A (ko) 2011-03-29 2016-04-25 로슈 글리카트 아게 항체 Fc 변이체
SG194111A1 (en) 2011-04-07 2013-11-29 Amgen Inc Novel egfr binding proteins
ES2686327T3 (es) 2011-08-23 2018-10-17 Roche Glycart Ag Moléculas de unión a antígeno biespecíficas
PE20141521A1 (es) 2011-08-23 2014-10-25 Roche Glycart Ag Moleculas biespecificas de union a antigeno activadoras de celulas t
US20130058936A1 (en) 2011-08-23 2013-03-07 Peter Bruenker Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
AR089028A1 (es) 2011-11-29 2014-07-23 Genentech Inc Composiciones y metodos para el analisis de cancer de prostata
CN102492772A (zh) 2011-12-02 2012-06-13 中国人民解放军军事医学科学院放射与辐射医学研究所 一种分子检测信号放大技术
WO2013086031A1 (en) 2011-12-05 2013-06-13 Nestec S.A. Method of therapy selection for patients with cancer
LT2794905T (lt) 2011-12-20 2020-07-10 Medimmune, Llc Modifikuoti polipeptidai, skirti bispecifinių antikūnų karkasams
US10254286B2 (en) 2012-01-24 2019-04-09 Pfizer Inc. Methods for detecting 5T4-positive circulating tumor cells and methods of diagnosis of 5T4-positive cancer in a mammalian subject
CN104125852B9 (zh) 2012-02-15 2017-05-17 弗·哈夫曼-拉罗切有限公司 基于Fc‑受体的亲和色谱
CA2870821C (en) 2012-04-20 2022-06-14 Merus B.V. Methods and means for the production of ig-like molecules
CN103792364B (zh) 2012-10-31 2016-06-08 张宝弘 用于检测外周血中循环肿瘤细胞ror1蛋白的试剂及其应用
WO2014165818A2 (en) 2013-04-05 2014-10-09 T Cell Therapeutics, Inc. Compositions and methods for preventing and treating prostate cancer
ES2651522T3 (es) 2013-12-16 2018-01-26 Humanitas Mirasole S.P.A. Altos niveles de FT de TEM para el diagnóstico del cáncer, en particular de cáncer colorrectal (CCR) y de páncreas (CP)
EP3083682B1 (en) 2013-12-20 2024-04-17 F. Hoffmann-La Roche AG Dual specific antibodies
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
WO2015161231A1 (en) 2014-04-17 2015-10-22 Siemens Healthcare Diagnostics Inc. Method to screen out false positives in a circulating tumor cell assay
EP3174897B1 (en) 2014-07-29 2020-02-12 F.Hoffmann-La Roche Ag Multispecific antibodies
CR20170032A (es) 2014-08-04 2017-04-04 Hoffmann La Roche Moleculas biespecíficas de unión a antígeno activadoras de células t
BR112017003236A2 (pt) 2014-09-12 2017-11-28 Genentech Inc anticorpos elaborados com cisteína, conjugados de droga e anticorpos, método de preparação de conjugado de droga e anticorpo e composição farmacêutica
CN107787332B (zh) 2015-04-24 2022-09-09 豪夫迈·罗氏有限公司 多特异性抗原结合蛋白
CN108064246A (zh) * 2015-06-15 2018-05-22 基因泰克公司 抗体和免疫结合物

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005113601A2 (en) * 2004-04-22 2005-12-01 Agensys, Inc. Antibodies and molecules derived therefrom that bind to steap-1 proteins
WO2008052187A2 (en) * 2006-10-27 2008-05-02 Genentech. Inc. Antibodies and immunoconjugates and uses therefor
CN106413756A (zh) * 2014-01-24 2017-02-15 豪夫迈·罗氏有限公司 使用抗steap1抗体和免疫缀合物的方法
WO2015149077A1 (en) * 2014-03-28 2015-10-01 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3

Also Published As

Publication number Publication date
KR20190136054A (ko) 2019-12-09
PH12019502274A1 (en) 2020-12-07
SG11201909218RA (en) 2019-11-28
US20200190212A1 (en) 2020-06-18
AU2018247767A1 (en) 2019-09-19
CA3055132A1 (en) 2018-10-11
JP7247101B2 (ja) 2023-03-28
US20240279355A1 (en) 2024-08-22
BR112019018767A2 (pt) 2020-05-05
RU2019134462A3 (enExample) 2021-07-13
CN110494452A (zh) 2019-11-22
MX2019011769A (es) 2019-11-07
EP3606963A1 (en) 2020-02-12
US12129306B2 (en) 2024-10-29
RU2019134462A (ru) 2021-05-05
KR102667951B1 (ko) 2024-05-22
PE20200010A1 (es) 2020-01-06
AU2018247767B2 (en) 2025-01-30
JP2020515277A (ja) 2020-05-28
ES2955852T3 (es) 2023-12-07
EP3606963B1 (en) 2023-08-30
CL2019002735A1 (es) 2020-01-17
CO2019010164A2 (es) 2019-10-21
US11685790B2 (en) 2023-06-27
US20220041747A1 (en) 2022-02-10
CR20190430A (es) 2019-11-01
MA49289A (fr) 2020-02-12
US11180571B2 (en) 2021-11-23
WO2018184966A1 (en) 2018-10-11
IL269394A (en) 2019-11-28
EP3606963C0 (en) 2023-08-30

Similar Documents

Publication Publication Date Title
US20240067749A1 (en) Antibodies binding to gprc5d
CN114174342B (zh) 与gprc5d结合的抗体
JP7061733B2 (ja) Ｃｄ３に結合する抗体
US12129306B2 (en) Antibodies binding to STEAP-1
CN114828965B (zh) 与hla-a2/mage-a4结合的抗体
CN111527107B (zh) 结合hla-a2/wt1的抗体
CN114174338A (zh) 与gprc5d结合的抗体
CN115916826A (zh) 与CD3和FolR1结合的抗体
JP2025503399A (ja) Ｃｄ３及びｐｌａｐに結合する抗体
JP7653881B2 (ja) Ｃｄ３に結合する抗体
HK40017330A (en) Antibodies binding to steap-1
HK40017330B (zh) 结合steap-1的抗体
HK40063378B (zh) 与cd3结合的抗体
HK40091593A (zh) 与cd3和folr1结合的抗体
HK40057663B (zh) 与cd3结合的抗体
HK40061355A (en) Antibodies binding to gprc5d
HK40064430A (en) Antibodies binding to nkg2d
HK40035560B (zh) 结合hla-a2/wt1的抗体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40017330

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant